Iqvia price target raised to $300 from $295 at UBS

UBS raised the firm’s price target on Iqvia to $300 from $295 and keeps a Buy rating on the shares. The company’s healthy backlog and tech/data-forward offering should enable market share gains, but Q2’s Technology & Analytical Solutions-driven beat and slightly softer than forecast R&D Solutions have mixed implications, the analyst tells investors.